Concentrated in oncology. Active in rare disease and gene & cell therapy. Extended on request into adjacent indications.

Coverage is organized around indications in which the pre-commercial vendor decision space is dense, the signal environment is legible from public sources, and the timing of engagement materially affects launch outcomes. Indications outside active coverage can be prepared as a custom brief within 48 hours of an initial conversation.